Jump to content



Photo

jeremy Siegel was on Bloomberg yesterday, he said inflation will


  • Please log in to reply
27 replies to this topic

#21 pdx5

pdx5

    I want return OF my money more than return ON my money

  • Traders-Talk User
  • 8,122 posts

Posted 19 November 2021 - 12:09 PM

 

 

There's just one little problem: the jabs don't work and may be worse than nothing: https://www.globalre...andates/5761305

 

But if  90% of people in our hospitals are not vaccinated and just a 10% are vaccinated (by the way these latter with symptoms of lower degree) what else do we need to say that vaccines are useful ?     

 

So wrong.  Here the vaccinated have risen from 6% months ago to now 46% because they are running out of juice.  I had Covid last November along with 4 friends. All just tested, 11 mths later full load of antibodies.  Natural is the only way to go! 

 

Nothing wrong with natural immunity. But they can not board you on a flight or a cruise ship based on your natural immunity because you do not have a easily readable document showing level of immunity you have. Official papers of covid vaccination are much easier for clerks to read. My recent cruise on Oasis of the Seas ship boarded 6000 passengers in less than 4 hours. No way they can have medically qualified people assessing natural immunity of un-vaccinated passengers in that time. It boils down to what is practical.


"Money cannot consistently be made trading every day or every week during the year." ~ Jesse Livermore Trading Rule

#22 hhh

hhh

    Member

  • Traders-Talk User
  • 602 posts

Posted 19 November 2021 - 12:48 PM

Gibraltar, most "vaccinated" in the world. Every citizen has at least two jabs and many have their third already. More cases every single day: 

 

https://www.worldome...ntry/gibraltar/

 

But "your doctor knows better" than actual epidemiology proving the darn things don't work because ad hominem and appeal to authority trump the truth every time, RIGHT? Not for this "nut case," but that's just me.

 

https://www.standard...ns-b966816.html



#23 andr99

andr99

    Member

  • Traders-Talk User
  • 5,955 posts

Posted 19 November 2021 - 01:34 PM

vaccination, social distancing, mask..........here we are doing well with these three simple weapons. You cannot enter a supermarket if you don' t wear a mask. Wherever you vaccinated man are.....you wear a mask and keep a safety distance. And hospitals are empty. To win a war you need infantry, aviation and navy.......three like we have deployed   


Edited by andr99, 19 November 2021 - 01:37 PM.

forever and only a V-E-N-E-T-K-E-N - langbard


#24 pdx5

pdx5

    I want return OF my money more than return ON my money

  • Traders-Talk User
  • 8,122 posts

Posted 19 November 2021 - 05:17 PM

Gibraltar, most "vaccinated" in the world. Every citizen has at least two jabs and many have their third already. More cases every single day: 

 

https://www.worldome...ntry/gibraltar/

 

But "your doctor knows better" than actual epidemiology proving the darn things don't work because ad hominem and appeal to authority trump the truth every time, RIGHT? Not for this "nut case," but that's just me.

 

https://www.standard...ns-b966816.html

You have no clue how vaccines work. Vaccines DO NOT BUILD A VALVE in your nose to block virus material floating in if you are alive and breathing in. That inhaled virus WILL INFECT your respiratory system. Only function of vaccines is to create anti-bodies for the particular signature of virus. After the virus material is in your lungs, it WILL START replicating. Only then the body becomes aware of the invasion. The virus never rings a bell upon entry. Virus never inquires if one is vaccinated or not.

 

If the vaccine has created enough anti-bodies, ODDs are you will subdue the virus before it makes you seriously sick. But infection has already taken place, so you can test positive. That  number of cases you mentioned in Gibraltar is not the critical number at all. People got vaccinated and began more mixing with others because they felt more confident. That is natural behavior.

 

The critical number is NOT cases, it is how many of the vaxxed died versus the unvaxxed.

Again, this is REAL data from a REAL hospital in Florida, and it clearly shows 85%+ of those sick enough to need hospitalization were UNvaxxed.

 

2021-08-27-10-04-31-Coronavirus-COVID-19


Edited by pdx5, 19 November 2021 - 05:18 PM.

"Money cannot consistently be made trading every day or every week during the year." ~ Jesse Livermore Trading Rule

#25 bigtrader

bigtrader

    Member

  • Traders-Talk User
  • 439 posts

Posted 19 November 2021 - 09:30 PM

Gibraltar, most "vaccinated" in the world. Every citizen has at least two jabs and many have their third already. More cases every single day: 

 

https://www.worldome...ntry/gibraltar/

 

But "your doctor knows better" than actual epidemiology proving the darn things don't work because ad hominem and appeal to authority trump the truth every time, RIGHT? Not for this "nut case," but that's just me.

 

https://www.standard...ns-b966816.html

Good grief man,

gesh


No longer interested in debating with IGNORANT people.


#26 hhh

hhh

    Member

  • Traders-Talk User
  • 602 posts

Posted 19 November 2021 - 11:06 PM

Ironically, you claim I have no clue how vaccines work and you deny the existence of mucosal vaccines. The mucosal portion of the immune system is the largest and most important. I'll give you credit for admitting that these jabs don't prevent or even lower the rate of infection, which is contrary to what the media, the POTUS, and many other misinformation artists have claimed for over a year and a half now, while even the manufacturers themselves claim no such thing. I absolutely agree with you that the public has been sold a false promise of safety which no doubt made many believe they were protected when they were actually twice as vulnerable to infection (proven by UK government data.)

 

These jabs give you fleeting mild to moderate symptom reduction per the endpoints of the manufacturers' studies. They do this by stimulating a fraction of your immune system to respond to one of 29 proteins contained in the SARS-CoV-2 virus. Unfortunately that is done by turning your body into a factory for this spike protein which is itself toxic, hence the less than rare clotting issues seen all over the world, especially in young males.

 

I believe it is a crime against humanity with absolutely no justifiable risk/reward to inject children with this experimental gene therapy with a worse risk profile than the disease it doesn't protect them from. I predict a huge increase in cardiac events in children in the coming months. The media (pharma's PR section) have already softened us up with "it's normal" advertisements.



#27 claire

claire

    Member

  • Traders-Talk User
  • 570 posts

Posted 20 November 2021 - 12:08 AM

Ironically, you claim I have no clue how vaccines work and you deny the existence of mucosal vaccines. The mucosal portion of the immune system is the largest and most important. I'll give you credit for admitting that these jabs don't prevent or even lower the rate of infection, which is contrary to what the media, the POTUS, and many other misinformation artists have claimed for over a year and a half now, while even the manufacturers themselves claim no such thing. I absolutely agree with you that the public has been sold a false promise of safety which no doubt made many believe they were protected when they were actually twice as vulnerable to infection (proven by UK government data.)

 

These jabs give you fleeting mild to moderate symptom reduction per the endpoints of the manufacturers' studies. They do this by stimulating a fraction of your immune system to respond to one of 29 proteins contained in the SARS-CoV-2 virus. Unfortunately that is done by turning your body into a factory for this spike protein which is itself toxic, hence the less than rare clotting issues seen all over the world, especially in young males.

 

I believe it is a crime against humanity with absolutely no justifiable risk/reward to inject children with this experimental gene therapy with a worse risk profile than the disease it doesn't protect them from. I predict a huge increase in cardiac events in children in the coming months. The media (pharma's PR section) have already softened us up with "it's normal" advertisements.

Read through this sample of peer reviewed studies cited in highly esteemed medical publications such as the NEJM which are a sample of information that refutes just about everything you seem to believe. Note: Adverse effects of the vaccine are seen in <0.01% while those adverse effects are seen in far higher percentages among those who had Covid.  Also take note of Post-Infectious Covid syndromes that affect 10%-30% of those who were infected.

 

 

Evaluation of the BNT162b2 COVID-19 vaccine in children 5 to 11 years of age.external icon Walter et al. NEJM (November 9, 2021).

Key findings:

  • In children aged 5–11 years, BNT162b2 (Comirnaty, Pfizer/BioNTech) vaccine efficacy for prevention of COVID-19 was 90.7% (95% CI 67.4%-98.3%) (Figure).
  • SARS-CoV-2 neutralizing antibody titers 1 month after dose 2 among 5–11-year-olds (10 µg dose) were similar to those among 16–25-year-olds who received 30 µg doses (geometric mean ratio was 1.04, 95% CI 0.93-1.18).
  • BNT162b2 10 µg doses had a favorable safety profile among 5–11-year-olds (Figure).
    • No serious vaccine-related adverse events were noted.

Methods: Ongoing phase 2–3 safety, immunogenicity, and efficacy trial of BNT162b2 vaccination in healthy children aged 5–11 years. Children were randomly assigned to receive either two 10 µg doses of BNT162b2 21 days apart or placebo; 1,517 received BNT162b2 and 751 received placebo. Vaccine efficacy was assessed ≥7 days after dose 2. Immune responses 1 month after dose 2 were immunologically bridged to those of 16–25-year-old participants from the pivotal trialexternal icon of 2 BNT162b2 30 µg doses. Limitations: Short duration of follow up (median 2.3 months); study likely under-powered to detect rare adverse events.

Implications: Two 10 µg doses of BNT162b2 vaccine were safe, immunogenic, and efficacious in children 5–11 years of age.

 

Note: Adapted from Walter et alPanel A shows the cumulative incidence of the 1st occurrence of COVID-19 after BNT162b2 dose 1 or placebo. Each symbol represents cases of COVID-19 on a given day. Panel B shows systemic events reported within 7 days after vaccine dose 1 (n = 1,511) and dose 2 (n = 1,501) and placebo (dose 1, n = 748 or 749; dose 2, n = 740 or 741 [number of children reporting at least 1 “yes” or “no” for the event after each dose]). Bar colors refer to adverse event severity: mildmoderateseveregrade 4. Numbers above bars are percentage of participants in each group. I bars represent 95% CIs. From the New England Journal of Medicine, Walter et al., Evaluation of the BNT162b2 COVID-19 vaccine in children 5 to 11 years of age. November 9, 2021, online ahead of print. Copyright © 2021 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.

Distinct SARS-CoV-2 antibody reactivity patterns elicited by natural infection and mRNA vaccinationexternal icon. Assis et al. NPJ Vaccines (November 4, 2021).

Key findings:

  • Specimens from mRNA-vaccinated healthcare workers demonstrated higher antibody levels to the SARS-CoV-2 spike protein S1 and receptor binding domains (RBD) than specimens from a community sample of unvaccinated seropositive persons (Figure).
    • When exposed to RBD domains from the Alpha (B.1.1.7), Beta (B.1.351), Delta (B.1.617.2), and wild-type lineages, higher anti-RBD antibody titers were observed in plasma from vaccinated persons than in plasma from people who recovered from confirmed COVID-19 (Figure).
  • Specimens from mRNA-vaccinated healthcare workers had greater anti-RBD reactivity than specimens from unvaccinated hospitalized COVID-19 patients who required ICU care.

Methods: Samples were obtained from 2 ongoing COVID-19 longitudinal serological surveys of Orange County, CA residents (July and December 2020) and healthcare workers (May and December 2020–March 2021) and a hospital biorepository of samples from 93 hospitalized patients. IgG levels were determined using a multiplex antigen microarray containing antigens from SARS-CoV-2. Limitations: Unclear severity and timing of participants’ infections and timing of vaccination; SARS-CoV-2 exposure may have differed between groups; specimens collected during pre-Delta period.

Implications: mRNA vaccination appears to induce a broader antibody response than SARS-CoV-2 infection.

 

Figure:

 

Note: Adapted from Assis et al. Natural exposure (from Santa Ana cohort, December 2020) vs. mRNA vaccination (from February/March 2021 cohort) antibody reactivity against (a) SARS-CoV-2 antigens, and (B) RBD from Alpha, Beta, Delta, and Mink variants, and wild-type (WT) virus. Mean fluorescence intensity (MFI) signals for antibodies are plotted. The boxes represent the 1st quartile, median, and 3rd quartile and the whiskers extend 1.5 times the interquartile range (IQR). Wilcoxon test was performed for pairwise comparisons and p values <0.01 were considered significant and represented as **. Licensed under CC BY 4.0.

Three doses of COVID-19 mRNA vaccination are safe based on adverse events reported in electronic health records.external icon Niesen et al. medRxiv (November 9, 2021).

Key findings:

  • Reports of severe adverse events after a 3rd dose of a COVID-19 mRNA vaccine were rare.
    • Pericarditis, anaphylaxis, myocarditis, and cerebral venous sinus thrombosis after dose 3 were reported for ≤0.01% of vaccinated persons (similar to the occurrence after dose 2) (Figure).
  • Fatigue, lymphadenopathy, nausea, and headache were reported slightly more often after dose 3 than dose 2 (Figure).

Methods: Retrospective study of patients vaccinated with 3 doses of BNT162b2 (Comirnaty, Pfizer/BioNTech, n = 38,094) or mRNA-1273 (Moderna, n = 9,905), December 1, 2020–October 17, 2021. Electronic health records were used to identify adverse events in the 2 weeks prior to the 1st dose and 2 weeks following the 1st, 2nd, and 3rd doses. Limitations: Limited to signs/symptoms included in electronic health records; persons who experienced post-vaccine adverse events might be less likely to get subsequent doses; results may not be generalizable.

Implications: The risk of severe adverse events after a 3rd dose of COVID-19 mRNA vaccine is low and comparable to the risk after a 2nd dose.

Figure:

 

Note: Adapted from Niesen et al. Prevalence of vaccine-associated adverse events in 3-dose vaccinated individuals during the 14-day period before 1st doseafter 1st doseafter 2nd dose, and after 3rd dose in (a) individuals that received 3 doses of BNT162b2, and (B) individuals that received 3 doses of mRNA-1273. Error bars indicate 95% confidence intervals, and asterisks indicate adverse events with significant (two-tailed p-value <0.05) difference in prevalence after the 3rd dose, compared with before the 1st dose (blue asterisk) or after the 2nd dose (orange asterisk). Used by permission of authors.

PEER-REVIEWED

Burdens of post-acute sequelae of COVID-19 by severity of acute infection, demographics and health status.external icon Xie et al. Nature Communications (November 12, 2021).

Key findings:

  • Among U.S. veterans with COVID-19, the overall excess burden of ≥1 post-COVID condition was 73.43 (95% CI 72.10-74.72) per 1,000 persons at 6 months.
    • Conditions with the largest excess burdens included shortness of breath (28.80 per 1,000 persons), sleep disorders (19.51), and hyperlipidemia (17.09) (Figure).
  • Excess burden of post-COVID conditions was 360.16 per 1,000 persons in those admitted to an ICU, 217.08 in hospitalized patients, and 44.51 in non-hospitalized patients.

Methods: Retrospective cohort study of COVID-19 patients who tested positive March 2020–March 2021 (n = 181,384) and uninfected controls (n = 4.4 million) using Veterans Health Administration data. Outcomes ascertained from 30 days after infection until the end of follow-up. Burden defined as having conditions in excess of the uninfected control group; models adjusted for multiple factors, including comorbid conditions. Limitations: Predominantly male participants; burdens may be underestimated if conditions not recorded in medical records; findings might not be generalizable.

Implications: Post-COVID conditions encompass a wide range of syndromes and likely pose significant challenges to patients and the U.S. healthcare system.

Figure:

 

Note: Adapted from Xie et al. Risks and burdens of post-COVID conditions. Hazard ratio (HR) and 95% CIs are presented in the left panel and burdens per 1,000 COVID-19 patients at 6 months are presented in the right panel; right limit of the bar represents estimated burden and error bars represent the 95% CI. Estimated burden was defined as having conditions in excess of the control group. Licensed under CC BY 4.0.

PEER-REVIEWED

Disparities in COVID-19 outcomes by race, ethnicity, and socioeconomic status: A systematic-review and meta-analysisexternal icon. Magesh et al. JAMA Network Open (November 11, 2021).

Key findings:

  • In a meta-analysis of 68 studies (>4 million persons), Black or African American individuals and Hispanic or Latino individuals were more likely than White individuals to test positive for COVID-19 (Figure).
    • Asian American individuals had the highest risk of ICU admission (Figure).
  • Among Black or African American individuals, lower county median income was associated with increased rates of test positivity and mortality.
    • Among Hispanic/Latino individuals, the linear association between median income and morbidity or mortality was inconsistent and differed by study type (cross-sectional vs. cohort).

Methods: Systematic review and meta-analysis of 68 U.S. based-studies (>4 million individuals) that were published January 1, 2020–January 6, 2021. Data were pooled using a random-effects model. Metaregression conducted to evaluate adjusted associations. Limitations: Race/ethnicity data missing for large proportion (~40%) of individuals; incomplete data for several racial and ethnic groups prevented inclusion of these groups in some analyses; many studies lacked variables of interest; susceptible to biases of included studies.

Implications: Even after correction for demographic and socioeconomic factors, COVID-19 positivity and ICU admission varied by race/ethnicity. Socioeconomic and racial inequities should be factored into efforts to reduce COVID-19 incidence and mortality.

Figure:

 

Note: Adapted from Magesh et al. Adjusted, sex-adjusted, and sex- and age-adjusted risk ratios (RRs) for African American, Hispanic/Latino, and Asian American individuals (compared with White individuals) according to COVID-19 positivity, hospitalization, ICU admission, and mortality. Licensed under CC BY.

Supporting health equity through data-driven decision-making: A local health department response to COVID-19.external icon Hansotte et al. American Journal of Public Health (October 28, 2021).

Key findings:

  • The Marion County Public Health Department (Indiana) integrated COVID-19 case data from multiple sources, created a community-based dashboard, solicited input and support from long-standing partners with community influence, and used the data and partner input to strategically place testing sites near populations with higher disease burden.
  • Testing rates increased and case rates declined among Black or African American, Hispanic/Latino, and Burmese residents in the 2 months after strategic placement of testing sites and the launch of information campaigns for the communities of interest (Figure).

Methods: Trends of COVID-19 cases and tests over time were examined in relation to dates testing sites were opened, March 2020–January 2021. Limitations: Non-experimental design and no control of confounding factors, findings might not be generalizable to other populations.

Implications: A data- and community-based, integrated intervention by local public health partners may contribute to more equitable access to COVID-19 testing.

Figure:

 

Note: Adapted from Hansotte et al. COVID-19 cases per 100 000 by race/ethnicity: Marion County, IN, March 6, 2020–January 27, 2021 showing trends among Asian (including Burmese)Hispanic or LatinoBlack or African American, and White residents. Dotted vertical lines indicate opening dates of MCPHD community testing sites: A = Eastside church (near Black or African American communities), B = educational campus (Hispanic or Latino communities), C = Westside racetrack (Hispanic or Latino communities), D = Marion County Public Health Department main site, E = Southside clinic (Burmese communities), F = Westside commercial, G = county fairgrounds. Permission request in process.

Vaccines

Variants

 

Note: Adapted from Lassauniere et al. SARS-CoV-2 neutralizing antibody titers against variants of concern Alpha, Beta, Gamma, and Delta lineage/sub-lineages B.1.617.2, AY.4, AY.4.2, and B.1.617.2+E484K, 2 months after the 2nd dose of BNT162b2 vaccination. Neutralization titers for variants of concern Alpha, Beta, and Gamma were available for 11 of 14 vaccinated sera. Licensed under CC BY 4.0.

  • SARS-CoV-2 Delta vaccine breakthrough transmissibility in Alachua, Floridaexternal icon. Magalis et al. medRxiv (Preprint; November 11, 2021). Viral load (VL) among breakthrough cases infected with the Delta variant (n = 56) and those infected with other variants (n = 13) were similar. When compared with unvaccinated age- and gender-matched cases infected with Delta (n = 36) or other variants (n = 75), Delta breakthroughs exhibited 38% lower VL than unvaccinated Delta cases (p <0.00001).

 

Note: Adapted from Magalis et al. VL distribution in vaccinated and unvaccinated SARS-CoV-2 infected patients. Each box plot (with line at median and red dot indicating the mean) represents a group of patients infected with either the Delta variant or other variants according to the legend in the figure. For each group pair, a two-tailed Mann–Whitney U test was executed. P-value and effect size are shown on top for those comparisons between groups that were significant at the 5% level after Bonferroni correction for multiple tests. Licensed under CC-BY-NC-ND 4.0.

Natural History, Reinfection, and Health Impact

1119_fig1-8.png?_=53660

 

Note: Adapted from Garcia-Valtanen et al. Patient serum neutralization end-point cut-off titers (highest dilution factor that yields ≥50% inhibition of cell death after live virus infection) at 12 months against ancestral wild-typeAlpha (B.1.1.7)Beta (B.1.351), Gamma (P.1) and Delta (B.1.617.2) live virus particles. Forty was the initial dilution for all serum samples. Neutralization activity was considered negative, value of zero, when neutralization of initial serum dilution was <50%. Licensed under CC-BY-NC-ND 4.0.

 

  • From the Morbidity and Mortality Weekly Report (November 19, 2021).


#28 hhh

hhh

    Member

  • Traders-Talk User
  • 602 posts

Posted 24 November 2021 - 12:10 AM

Highly esteemed indeed, New England Journal of Misinformation

https://davidhealy.o...misinformation/